Mutations in the GLRA1 gene, which encodes the a1-subunit of the inhibitory glycine receptor (GlyR), are the underlying causes in the majority of cases of hereditary startle disease (OMIM no. 149400). GlyRs are modulated by alcohols and volatile anesthetics, where a specific amino acid at position 267 has been implicated in receptor modulation. We describe a hyperekplexia family carrying the novel dominant missense allele GLRA1(S267N), that affects agonist responses and ethanol modulation of the mutant receptor. This study implies that a disease-related receptor allele carries the potential to alter drug responses in affected patients.
Introduction
Strychnine-sensitive glycine receptors (GlyRs) mediate fast synaptic inhibition in mammalian spinal cord and brainstem. GlyRs belong to the nicotinic acetylcholine receptor superfamily of ligand-gated ion channels. The hypertonic motor disorder hyperekplexia (STHE, OMIM no. 149400), 1 is caused primarily by mutant alleles of the glycine receptor a1 gene (GLRA1; NM_000171.2), while alterations of the glycine transporter GLYT2 (NM_004211.3) have also been observed. 2 -4 In the neonate, the disease manifests itself as stiff baby syndrome, while exaggerated startle responses predominate in the adult. Dominant forms of STHE have been attributed to mutations within the pore-lining transmembrane segment TM2 and adjacent regions, while recessive cases result from mutations within TM1 5 and from a null allele of GLRA1. 6 GlyRs are molecular targets for alcohols and anesthetics 7 where modulation was attributed to a serine residue at position a1(267). 7, 8 Here,
we report the novel allele GLRA1(S267N), associated with dominant hyperekplexia. Electrophysiological and biochemical properties of the mutant channels were examined in HEK293 cells.
Patients and methods

Patients
Following the guidelines of the Local Ethics Committee, informed consent was obtained from the family for electrophysiological studies and mutation analysis of the GLRA1 and GLRB genes. Symptoms of stiff baby syndrome in the index patient (30-3, age ¼ 5 weeks) were diagnosed clinically shortly after birth, while his father (30-1, age ¼ 28 years) displayed the hallmark features of hyperekplexia in an adult. The mother of the patient was unaffected. After birth, patient 30-3 suffered from severe muscular hypertonia and hyperreflexia. Upon neurophysiological examination, startle responses affecting muscles of the head, neck and upper arms could be elicited by acoustic stimuli: reflex latencies from the masseter, trapezius and sternocleidomastoid muscles were shortened (o22 ms) and followed by an abnormal blink reflex (M. orbicularis oculi: 23-26 ms). In contrast, the symptoms of the patient's father were less pronounced: exaggerated brain stem reflexes were found by neurophysiological testing, but no acoustic startle could be elicited. In both patients, multiple EEG recordings were not indicative of epilepsy. The father of the patient reported no subjective differences in ethanol sensitivity.
Molecular analysis
Polymorphism analysis DNA was extracted from EDTAblood using a standard protocol. For initial screening, MALDI-TOF MS-based genotyping of known GLRA1 polymorphisms was performed as described previously. 9 Direct sequencing was performed using an Automated DNA Sequencer (ABI -Perkin Elmer, 377A).
Mutagenesis and expression The mutation G1180A was introduced into a GLRA1 cDNA plasmid. HEK293 cells were transfected by CaPO 4 and utilized after 48 -72 h.
Electrophysiology recordings and data analysis Whole cell currents were recorded at 22 -241C and a holding potential of À60 mV using a U-tube for rapid agonist delivery and an EPC 9 recording system (HEKA Electronics, Germany) as described previously. 10 
Results
Identification of GLRA1(S267N)
Genomic DNA was subjected to initial MALDI -TOF MS genotyping. 9 After known mutations were excluded, GLRA1 amplimers were sequenced directly. Affected individuals were heterozygous for the substitution GLRA1 (G1180A) in exon 7 ( Figure 1a ). This was confirmed by multiplex MALDI -TOF MS genotyping 9 where the S267N allele was identified in the patient sample ( Figure 1b ). GLRA1(G1180A) predicts an asparagine instead of a serine . MALDI-TOF-MS spectra of the homozygous wild-type allele (control), and the heterozygous S267N allele (arrowhead, patient). Unextended primers (P-K276, 4489 Da; P-S267, 5398 Da; P-I244, 6364 Da) were used for internal mass calibration. For the S267N allele, the molecular mass of 6000 Da represented the wild-type G-allele (wt), while the molecular mass of 5695 Da indicated the mutated allele (G1180A). Alleles I244 (T1111A) and K276E (A1206G) were not present in the patient.
residue at position 267 of GlyRa1. According to topology predictions, S267 locates to transmembrane domain 2 (TM2) close to the extracellular opening of the channel 11 and is conserved between human and murine GlyRasubunits.
Electrophysiological studies
Constructs carrying the mutation GLRA1(G1180A) were transfected transiently into HEK293 cells. GlyR surface expression in membranes of a1S267N-transfected cells was unchanged from a1WT cells, as assessed by immunoblotting (data not shown). Whole-cell recordings showed no significant differences in maximum currents at between a1WT (I max ¼ 6.3±1.7 nA) and a1S267N (I max ¼ 5.4±1.7 nA, 3 mM glycine, n ¼ 10 each). Concentration -response analyses for glycine yielded a E17-fold reduction of the apparent affinity in a1S267N homomers compared to the wild type (Figure 2a ). Apparent glycine affinity was reduced B2.3-fold for cells co-transfected with equimolar amounts of a1WT and a1S267N plasmid ( Figure 2a) . As synaptic GlyRs are thought to contain 2a1 and 3b subunits, 12 a1WT, b and a1S267N constructs were (Figure 2a) . While b-alanine and taurine are full agonists of wild-type GlyRs, both ligands act as either partial agonists or competitive antagonists in GlyRs with mutations in the intracellular or extracellular loops adjacent to TM2. 13 Indeed, b-alanine and taurine showed a decreased efficacy on a1S267N GlyRs, eliciting only 17% (b-alanine, n ¼ 11), and 2% (taurine, n ¼ 8) of the maximum glycine response at 1 mM agonist (Figure 2b ). Doseresponse analysis for b-alanine on a1S267N GlyRs could be fitted under the assumption that K D and I max were unchanged, and only channel opening was affected (Figure 2c ), consistent with literature data. Figure 2d ), corresponding to a E15-fold reduced binding affinity. Binding affinities were diminished E21-and 15-fold for b-alanine and taurine, respectively, in a1S267N GlyRs (Figure 2d ). The mutation a1S267N thus causes reduced agonist binding which is compatible with a reduced channel opening efficacy for partial agonists.
Ethanol modulation of a1S267N GlyRs
Ethanol sensitivity of recombinant GlyRs depends on both, the expression system used 14 and the agonist concentration applied. 15 Here, modulation of glycine-induced currents by alcohols was observed in B50% of cells at agonist concentrations of EC 10 -20 . For a1WT, glycine responses were doubled following preincubation with 200 mM ethanol while potentiation of a1S267N was nearly absent (Figure 3a and b) . Ethanol effects (200 mM) were quantified in [ 3 H]strychnine binding assays with membranes carrying a1WT, a1S267N or a1S267Y, a mutation in which ethanol inhibited glycinergic currents. 16 For a1WT
and a1S267N, the apparent K D was shifted leftward with ethanol (Figure 3c and d) . In contrast, the K D in a1S267Y was shifted rightward, consistent with inhibition by ethanol (Figure 3e) . Ethanol modulation at 25 nM of [ 3 H]strychnine (Figure 3f ) revealed an almost two-fold increase of binding to a1WT membranes (Po0.01); no change was observed for a1S267N, and strychnine binding was reduced in a1S267Y membranes (Po0.05). Thus, the mutation a1S267N affects ethanol sensitivity of the glycine receptor a1-subunit.
Discussion
In this study, we identified the novel hyperekplexia allele GLRA1(S267N) that affects the ethanol modulatory site within the glycine receptor transmembrane segment 2 of the a1-subunit. This disease-associated GLRA1 allele encodes the substitution of a serine for an asparagine residue that has been characterized in previous in vitro studies to affect the GlyR modulation by alcohols and volatile anesthetics. 8 Moreover, transfer of the mutation a1S267Q
into knock-in mice produced all hallmark features of dominant hyperekplexia. This indicates that not only ethanol modulation is linked to position a1S267, but also motor function is influenced in the animal model.
17
A number of mutations associated with dominant hyperekplexia have been described within TM2. 5 According to current structural models, a1S267, the neighboring a1Q266 and a1V260M are localized to the TM2 domain of the GlyR. 18 Impairments found in these receptor mutants are similar: notably, the reduced sensitivity to glycine as well as the conversion of b-alanine and taurine into competitive antagonists. 13 It should be noted that the conversion of the endogenous GlyR agonists, b-alanine and taurine, to functional antagonists carries the potential to further aggravate the dysfunction associated with hyperekplexia. A transgenic mouse carrying another ethanol resistant substitution, a1S267Q, exhibits diminished sensitivity to ethanol in behavioral tests, 19 indicating that some effects of ethanol can be correlated to a defined site in the glycine receptor. Heterozygous animals (a1/a1S267Q) display enhanced acoustic startle reactions, thus reflecting the dominant effect of the mutation. Upon heterologous expression, a1S267 substitutions differ with respect to their electrophysiology. In a1S267N receptors, we observed an increased EC 50 for glycine and no change in I max , while a1S267Q channels exhibit a normal EC 50 and reduced I max. 17 The phenotypic presentation in both cases, however, is compatible with dominant hyperekplexia. While ethanol potentiation was virtually absent in HEK293 expressed homomeric a1(S267N) receptors, some ethanol sensitivity is retained in Xenopus oocyte expression, as potentiation depends on the expression system. 14, 17 This study shows that a disease-related receptor allele harbours the potential to modify drug responses in affected patients by reducing GlyR affinity and efficacy. Given the low phenotypic penetrance of the disease allele GLRA1(S267N) in one of our patients, however, this allelic polymorphism may not be clinically apparent. Hence, idiosyncratic drug responses may be attributed to an as yet unrecognized disease allele. 
